Head and Neck Squamous Cell Carcinoma-Epidemiology Forecast to 2030

Head and Neck Squamous Cell Carcinoma-Epidemiology Forecast to 2030

  • GlobalData
  • August 2021
  • Pharmaceutical
  • 56 pages

Report Description

Head and neck cancers (HNCs) are a heterogeneous group consisting of cancers of the mouth, including the lip, tongue, gum, floor of mouth, palate, and other parts of mouth (ICD-10 code = C00-C06),; the salivary glands (ICD-10 code = C07-C08); the pharynx, including the tonsil, oropharynx, nasopharynx, pyriform fossa, hypopharynx, other mouth/pharynx (ICD-10 code = C09-C14); the nose, sinuses, and related structures (ICD-10 code = C30-C31), and the larynx (ICD-10 code = C32) (World Health Organization, 2011). HNCs usually begin in the squamous cells that line the moist mucosal surfaces of the tissues and organs of the head and neck. It is estimated that more than 80% of all oral cavity and pharynx cancers are squamous cell carcinomas (Howlader et al., 2020; National Cancer Institute, 2021).

In the 8MM, the diagnosed incident cases of HNC are expected to increase from 279,734 cases in 2020 to 338,790 cases in 2030, at an Annual Growth Rate (AGR) of 2.11%. In 2030, urban China will have the highest number of diagnosed incident cases of HNC in the 8MM, with 141,960 diagnosed incident cases, whereas Italy will have the fewest diagnosed incident cases with 13,720 cases. In the 8MM, the five-year diagnosed prevalent cases of HNC are expected to increase from 836,755 cases in 2020 to 1,018,417 cases in 2030, at an AGR of 2.17%. GlobalData epidemiologists attribute the increase in the five-year diagnosed prevalent cases and diagnosed incident cases of HNC to diagnosed incidence rate, regression trend analysis and survival rates, and population dynamics in each market.

Scope

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for HNCs in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China). The report provides a 10-year epidemiological forecast of the diagnosed incident cases of HNCs. In this analysis, HNCs are grouped into the following groups -

  •  Cancers of the lip, oral cavity, pharynx, and larynx cancer (ICD10 = C00C06, C09, C12C14, C32, and C10 [HPV]); Oropharynx cancer (ICD10 = C10); Nasopharynx cancer (ICD10 = C11); Other HNC sitessalivary gland and nose, sinuses, and other related structures cancer (ICD10 = C07C08 and C30C31).
  •  Each of the four groups is further segmented by risk factor (tobacco smoking history), histology distribution (squamous cell and nonsquamous cell), and clinical stage at diagnosis among the squamous cell carcinomas. In addition, the diagnosed incident cases of oropharynx cancer were further segmented by risk factor (human papillomavirus infection status HPV+ and HPV) and the diagnosed incident cases nasopharynx cancer were segmented by the risk factor of Epstein Barr virus infection (EBV+). The report provides a 10year epidemiological forecast of the fiveyear diagnosed prevalent cases of each of the four groups.
  •  The HNC epidemiology report is written and developed by Masters and PhDlevel epidemiologists.
  •  The Epidemiology Report is indepth, high quality, transparent and marketdriven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

The HNCs Epidemiology series will allow you to 

  •  Develop business strategies by understanding the trends shaping and driving the global HNCs market.
  •  Quantify patient populations in the global HNCs market to improve product design, pricing, and launch plans.
  •  Organize sales and marketing efforts by identifying the age groups that present the best opportunities for HNCs therapeutics in each of the markets covered.
  •  Understand magnitude of HNCs by stage at diagnosis, risk factors, EGFR mutation, PDL1 expression by CPS scores, and surgical and radiotherapy vs. systemic treatment.

Have query on this report?

Make an Enquiry

Table of Contents

1 Head and Neck Squamous Cell Carcinoma: Executive Summary

1.1 Catalyst
1.2 Related Reports
1.3 Upcoming Reports

2 Epidemiology
2.1 Disease Background
2.2 Risk Factors and Comorbidities
2.3 Global and Historical Trends
2.4 8MM Forecast Methodology
2.4.1 Sources
2.4.2 Forecast Assumptions and Methods
2.4.3 Forecast Assumptions and Methods: Diagnosed Incident Cases of HNC
2.4.4 Forecast Assumptions and Methods: Diagnosed Incident Cases of HNC by Histology Distribution
2.4.5 Forecast Assumptions and Methods: Diagnosed Incident Cases of HNC by Clinical Stage at Diagnosis for Squamous Cell Carcinoma
2.4.6 Forecast Assumptions and Methods: Diagnosed Incident Cases of Oropharynx Cancer by Risk Factor (HPV+ and HPV-)
2.4.7 Forecast Assumptions and Methods: Diagnosed Incident Cases of Nasopharynx Cancer by Risk Factor (EBV+)
2.4.8 Forecast Assumptions and Methods: Tobacco Smoking History
2.4.9 Forecast Assumptions and Methods: Five-Year Diagnosed Prevalent Cases of HNC
2.5 Epidemiological Forecast for HNC (2020-2030)
2.5.1 Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer (ICD-10 = C00-C06, C09, C12-C14, C32, and C10 [HPV-])
2.5.2 Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer (ICD-10 = C00-C06, C09, C12-C14, C32, and C10 [HPV-]) by Risk Factor, Histology Distribution, and Stage at Diagnosis
2.5.3 Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer (ICD-10 = C00-C06, C09, C12-C14, C32, and C10 [HPV-])
2.5.4 Diagnosed Incident Cases of Oropharynx Cancer (ICD-10 = C10)
2.5.5 Diagnosed Incident Cases of Oropharynx Cancer by Risk Factors, Histology Distribution, and Stage at Diagnosis
2.5.6 Diagnosed Incident Cases of Nasopharynx Cancer (ICD-10 = C11)
2.5.7 Age-Specific Diagnosed Incident Cases of Nasopharynx Cancer
2.5.8 Sex-Specific Diagnosed Incident Cases of Nasopharynx Cancer
2.5.9 Diagnosed Incident Cases of Nasopharynx Cancer by Risk Factors, Histology Distribution, and Stage at Diagnosis
2.5.10 Five-Year Diagnosed Prevalent Cases of Nasopharynx Cancer
2.5.11 Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer (ICD-10 = C07-C08 and C30-C31)
2.5.12 Age-Specific Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer
2.5.13 Sex-Specific Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer
2.5.14 Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer by Risk Factors, Histology Distribution, and Stage at Diagnosis
2.5.15 Five-Year Diagnosed Prevalent Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer
2.6 Discussion
2.6.1 Epidemiological Forecast Insight
2.6.2 COVID-19 Impact
2.6.3 Limitations of the Analysis
2.6.4 Strengths of the Analysis

3 Appendix
3.1 Bibliography
3.2 About the Authors
3.2.1 Epidemiologist
3.2.2 Reviewers
3.2.3 Global Director of Therapy Analysis and Epidemiology
3.2.4 Global Head and EVP of Healthcare Operations and Strategy
Contact Us

List of Tables

Table 1: Summary of Newly Added Data Types
Table 2: Summary of Updated Data Types
Table 3: Risk Factors and Comorbid Conditions Associated with HNCs
Table 4: 8MM, Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer by Risk Factor, Histology Distribution, and Stage at Diagnosis, Both Sexes, Ages 18 Years, N, 2020
Table 5: 8MM, Diagnosed Incident Cases of Oropharynx Cancer by Risk Factor, Histology Distribution, and Stage at Diagnosis, Both Sexes, Ages 18 Years, N, 2020
Table 6: 8MM, Diagnosed Incident Cases of Nasopharynx Cancer by Risk Factors, Histology Distribution, and Stage at Diagnosis, Both Sexes, Ages 18 Years, N, 2020
Table 7: 8MM, Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer by Risk Factor, Histology Distribution, and Stage at Diagnosis, Both Sexes, Ages 18 Years, N, 2020

List of Figures

Figure 1: 8MM, Diagnosed Incident Cases of HNC, Both Sexes, N, Ages 18 Years, 2020 and 2030
Figure 2: 8MM, Five-Year Diagnosed Prevalent Cases of HNC, Both Sexes, N, Ages 18 Years, 2020 and 2030
Figure 3: 8MM, Diagnosed Incidence of HNC, Men and Women (Cases per 100,000 Population), Ages 18 Years, 2020
Figure 4: 8MM, Sources Used, Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer (ICD-10 = C00-C06, C09, C12-C14, C32, and C10 [HPV-])
Figure 5: 8MM, Sources Used, Diagnosed Incident Cases of Oropharynx Cancer (ICD-10 = C10); Nasopharynx Cancer (ICD-10 = C11); Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer (ICD-10 = C07-C08 and C30-C31)
Figure 6: 8MM, Sources Used, Five-Year Prevalent Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer (ICD-10 = C00-C06, C09, C12-C14, C32, and C10 [HPV-]), Oropharynx Cancer (ICD-10 = C10), Nasopharynx Cancer (ICD-10 = C11), Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer (ICD-10 = C07-C08 and C30-C31)
Figure 7: 8MM, Sources Used to Forecast the Risk Factors and Histology Distribution Among Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer (ICD-10 = C00-C06, C09, C12-C14, C32, and C10 [HPV-]), Oropharynx Cancer (ICD-10 = C10), Nasopharynx Cancer (ICD-10 = C11), Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer (ICD-10 = C07-C08 and C30-C31)
Figure 8: 8MM, Sources Used to Forecast the Stage at Diagnosis Among Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer, Oropharynx Cancer, Nasopharynx Cancer, and Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer
Figure 9: 8MM, Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer, N, Both Sexes, Ages 18 Years, 2020
Figure 10: 8MM, Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer, N, Both Sexes, Ages 18 Years, 2020
Figure 11: 8MM, Diagnosed Incident Cases of Oropharynx Cancer, N, Both Sexes, Ages 18 Years, 2020
Figure 12: 8MM, Diagnosed Incident Cases of Nasopharynx Cancer, N, Both Sexes, Ages 18 Years, 2020
Figure 13: 8MM, Diagnosed Incident Cases of Nasopharynx Cancer by Age, N, Both Sexes, 2020
Figure 14: 8MM, Diagnosed Incident Cases of Nasopharynx Cancer by Sex, N, Ages 18 Years, 2020
Figure 15: 8MM, Five-Year Diagnosed Prevalent Cases of Nasopharynx Cancer, N, Both Sexes, Ages 18 Years, 2020
Figure 16: 8MM, Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer, N, Both Sexes, Ages 18 Years, 2020
Figure 17: 8MM, Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer by Age, N, Both Sexes, 2020
Figure 18: 8MM, Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer by Sex, N, Ages 18 Years, 2020
Figure 19: 8MM, Five-Year Diagnosed Prevalent Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer, N, Both Sexes, Ages 18 Years, 2020

Success Stories

Our Clients